Elsevier,

Nitric Oxide - Biology and Chemistry, Volume 134-135, 1 May 2023

Nitric Oxide can act as both protecting and aggravating factor in Alzheimer's Disease. Nitric oxide can be considered as a neurotoxic factor in Alzheimer's Disease. Nitric Oxide induces neuro plasticity, neuroprotection, neurogenesis, long-term potentiation, and myelination. Drugs based on Nitric Oxide have shown promising results in Alzheimer's Disease. Nitric Oxide can via sundry ways ameliorate memory formation.
This Article supports Sustainable Development Goal 3 by showing a positive association between hearing loss without hearing aid use and dementia in adults aged 40-69 years in the UK. The authors analysed all-cause dementia, as well as specific types including Alzheimer's disease. Hearing loss was associated with increased risk of dementia, and using hearing aids was associated with a similar risk of dementia to no hearing loss, suggesting that hearing aid use in people with hearing loss could reduce dementia risk.
The 2022 UN Climate Change Implementation Plan acknowledged the necessity of taking action to address climate change and safeguard water and food security within a human-rights-based approach.1 Low-income and middle-income countries are disproportionately affected by climate change and have less capacity to respond to climate-related impacts such as sea-level rise, extreme weather events, drought, population displacement, and disease.
Elsevier, Annals of Hepatology, Volume 28, 1 May 2023
Introduction and Objectives: We aimed to analyze the trends of total and sex-stratified mortality from hepatitis C virus (HCV) and to estimate the proportion of non-alcoholic liver disease deaths in M
Richard et al. provide extensive evidence suggesting that treatment with the HIV-1 attachment inhibitor temsavir can have beneficial effects that extend beyond viral neutralization, notably by preventing elimination of uninfected cells and induction of a cytokine burst caused by its soluble viral glycoprotein.
Dolutegravir is the globally recommended first-line therapy for HIV. In this paper researchers assess the effects of dolutegravir roll-out in the country with the highest HIV burden.
Early treatment of HIV is essential for the health of infants living with HIV; this study looks at ways to improve case-finding.
This Article supports SDG 3 by comparing epigenetic ageing during untreated HIV infection and during HIV being treated with antiretroviral therapy. They found that epigenetic ageing was accelarated during the former and decelerated during the latter.
This Article supports SDG 3 by evaluating the effects of a behavioural intersectional stigma coping intervention on stigma and care use. They found that the brief intervention did not change stigma manifestations or drug use behaviours but did reduce the impact of stigma as a barrier to care use.
This study supports SDG 3 by highlighting that coverage of opioid agonist treatment and syringe exchange programmes (which are associated with reducing HIV transmission) are low in most countries and for the majority of people who inject drugs; although coverage is improving, this is insufficient when compared with the indicator targets set out by WHO, UNAIDS, and the UN Office on Drugs and Crime.

Pages